Metabolic FDA-approved medicine

Injectable Vitamin C

IV Vitamin C · Ascorbic Acid (Injectable)

Evidence: Approved label. Example dose: finalize with a provider. Not a fact-check stamp.

1-25g IV or 500mg-2g IM – 500-1000 mg IM 1-3x weekly

Injectable vitamin C (ascorbic acid) is a parenteral formulation of the essential water-soluble vitamin, administered intravenously (IV) or intramuscularly (IM). Vitamin C is a potent antioxidant and essential cofactor for numerous enzymatic reactions including collagen synthesis, carnitine biosynthesis, and neurotransmitter production. At physiological concentrations, it functions primarily as an antioxidant, but at the supraphysiological plasma levels achievable only through IV administration (>200mg/dL), it exhibits pro-oxidant properties that have been investigated in oncology research.

Quick Start

Route

Intravenous (IV) or Intramuscular (IM)

Start low

1-25g IM

Frequency

1-3x weekly

Timing

No specific requirement

Starting dose. 1-25g — IV or 500mg-2g IM

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first

Conservative start

1-25g IV or 500mg-2g IM · Intravenous (IV) or Intramuscular (IM) · 1-3x weekly

conservative starter

1-25g IV or 500mg-2g IM

1-3x weekly

Intermediate

Immune & Antioxidant Flush

500-1000 mg · IM · 2x Weekly

human study · Padayatty et al. 2004 (Ann Intern Med)

Injections can be quite painful; frequently compounded with a small amount of lidocaine or administered via slow IV drip for massive doses. Note the route: the cited pharmacokinetic study used INTRAVENOUS vitamin C, and its finding is specifically that IV bypasses the gut limit to reach far higher plasma peaks. This card is intramuscular, which does not reproduce those peaks.

500-1000 mg

2x Weekly

◆

How it works

As an electron donor, ascorbic acid serves as a cofactor for prolyl and lysyl hydroxylases (essential for collagen synthesis), dopamine beta-hydroxylase (norepinephrine synthesis), and various dioxygenases involved in carnitine biosynthesis and gene regulation via epigenetic demethylation.

At pharmacological IV concentrations (>200mg/dL plasma), ascorbic acid generates hydrogen peroxide extracellularly through auto-oxidation. Cancer cells, which often have low catalase activity, are selectively vulnerable to this oxidative stress, while normal cells with adequate catalase can neutralize H2O2. This is the basis for high-dose IV vitamin C research in oncology.

Ascorbic acid supports immune function by enhancing neutrophil chemotaxis, phagocytosis, and oxidative burst capacity. It also supports lymphocyte proliferation and antibody production, and protects immune cells from oxidative damage during inflammatory responses.

What to expect

Early

Days 1–7

Days 1-7: Rapid plasma level elevation after IV/IM dosing. Deficiency symptoms (fatigue, poor healing) begin improving. Subjective energy boost reported by many.

Evidence

HumanStrong

AnimalPresent

In-vitroStrong

Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.

Evidence boundary from the checked abstract: Experimental data suggest that intravenous vitamin C may attenuate inflammation and vascular injury associated with sepsis and acute respiratory distress syndrome (ARDS).

Experimental data suggest that intravenous vitamin C may attenuate inflammation and vascular injury associated with sepsis and acute respiratory distress syndrome (ARDS).

Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. JAMA · 2019 · PMID 31573637

Evidence scope. This entry supports only the exact statement quoted from the live abstract; it does not independently verify OnePin's displayed dose, route, frequency, formulation, population, or broader mechanism.

Claims we could not support

No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.

Dose/route: 1-25g IV or 500mg-2g IM; Intravenous (IV) or Intramuscular (IM); 1-3x weekly. No checked live PubMed abstract verified this exact displayed dose, route, and frequency for the same molecule/formulation and relevant population.

Primary safety claim: Injection site pain and irritation (IM), vein irritation during infusion (IV). No checked live PubMed abstract directly verified this source-JSON safety claim at the displayed formulation, route, and regimen.

Interactions & stacking

Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.

Documented together

BPC-157No pharmacological conflict - administer in separate syringes at different sites

EpithalonAntioxidant support may complement telomerase activation - no adverse interaction

TB-500No direct interaction - vitamin C supports collagen synthesis while TB-500 promotes tissue repair

GlutathioneVitamin C regenerates oxidized glutathione (GSSG) back to reduced form (GSH) - synergistic antioxidant recycling

Keep separate

Injectable B-ComplexAscorbic acid degrades cyanocobalamin (B12) when mixed - never combine in the same syringe

Any compound in same syringeInjectable vitamin C is acidic (low pH) and can denature peptides and degrade other compounds - always administer alone

GHK-CuVitamin C is a reducing agent that can reduce Cu2+ to Cu1+, disrupting the copper-peptide complex essential for GHK-Cu activity

Methylene BlueVitamin C can reduce methylene blue to leucomethylene blue, altering its redox cycling and potentially negating its mitochondrial electron carrier function

Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.

Pharmacokinetics

Illustrative plasma concentration · 3.0 h

Half-life

~30 min

(IV), ~2 hours (IM). Renal elimination with dose-dependent kinetics.

Peak · Tmax

Immediate (IV), ~30-60 min (IM)

Elimination

~2-4 hours

(IV), ~8-10 hours (IM). Faster at high doses due to renal threshold excretion.

Bioavailability

~100%

IV/IM. Oral bioavailability is dose-limited (~70-90% at low doses, <50% at high doses due to saturable absorption).

Duration of action

4-8 hours

Tissue antioxidant effect persists longer

Clearance

Renal (dose-dependent tubular reabsorption; excess excreted as oxalate and ascorbate)

Storage. Store refrigerated at 2-8C. Protect from light. Ascorbic acid is sensitive to oxidation; discard if solution is darkened or discolored.

Regulatory status

FDA-approved for treatment and prevention of vitamin C deficiency (scurvy) and conditions requiring parenteral supplementation. High-dose IV use in oncology and sepsis is investigational/off-label.

Put it to work

Calculate, log & track

Open Injectable Vitamin C straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Injectable Vitamin C in the app →

Go deeper

The guide & community

The complete Injectable Vitamin C walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗

Open in app Community